Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
The HER-2/ neu oncogene is a member of the erb B-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor. This gene has been shown to be amplified in human breast cancer cell lines. In the current study, alterations of the gene in 189 primary human breast cancers were investigated. HER-2/ neu was found to be amplified from 2- to greater than 20-fold in 30% of the tumors. Correlation of gene amplification with several disease parameters was evaluated. Amplification of the HER-2/ neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. It retained its significance even when adjustments were made for other known prognostic factors. Moreover, HER-2/ neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-positive disease. These data indicate that this gene may play a role in the biologic behavior and/or pathogenesis of human breast cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CNVs are involved in a large number of complex human diseases such as Down’s syndrome (trisomy 21) and many cancers, for example HER2 gene amplification in breast cancer (BC) (1–5).”
From Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation (2012) · cites this paper as [5]
In the citing paper
“In a seminal study, Slamon et al. found that HER2 is amplified in about 20% of breast cancers (Slamon et al., 1987).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Slamon et al., 1987
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene
Greenberg, M. E., & Ziff, E. B. (1984) · Nature · doi:10.1038/311433a0 · Cited by 3,064
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804
Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,752
Self-citationClose similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, J., & Waterfield, M. D. (1984) · Nature · doi:10.1038/307521a0 · Cited by 2,516
Self-citationAmplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage
Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,262
Association of Multiple Copies of the N-myc Oncogene with Rapid Progression of Neuroblastomas
Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., & Hammond, D. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510313131802 · Cited by 2,010
Coussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Self-citation
Research works printed but not linked: 1
- Maniatis, T., Molecular Cloning: A Laboratory Manual: 282 (1982).
Cited by
Items 601–700 of 1,056
Chacón, R. D., & Costanzo, M. V. (2010) · Breast Cancer Research · doi:10.1186/bcr2574 · Cited by 239
Genomic Medicine: A Decade of Successes, Challenges, and Opportunities
McCarthy, J. J., McLeod, H. L., & Ginsburg, G. S. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005785 · Cited by 239
“In the mid-1980s, detailed molecular studies of breast tumors led to the discovery of HER-2, a biomarker overexpressed in about 30% of breast tumors and associated with adverse outcomes (17).”
BackgroundThe long term prognostic significance of c-erbB-2 in primary breast cancer
Winstanley, J. H. R., Cooke, T., Murray, G. D., Platt-Higgins, A. M., George, W. D., Holt, S., Myskov, M., Spedding, A., Barraclough, B. R., & Rudland, P. S. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.103 · Cited by 239
Maroulakou, I. G., Oemler, W., Naber, S. P., & Tsichlis, P. N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3782 · Cited by 238
“Overexpression of Neu activates multiple signaling pathways and is associated with poor prognosis (1).”
BackgroundThe prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases
Quénel, N., Wafflart, J., Bonichon, F., de Mascarel, I., Trojani, M., Durand, M., Avril, A. R., & Coindre, J. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00665980 · Cited by 238
“Much attention has been focused recently on the amplification of the cerbB2 oncogene associated with increased c-erbB2 oncoprotein expression [1].”
Backgroundc-erbB-2 oncoprotein expression in primary and advanced breast cancer
Lovekin, C., Ellis, I., Locker, A., Robertson, J., Bell, J., Nicholson, R., Gullick, W., Elston, C., & Blamey, R. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.101 · Cited by 237
“…have confirmed a relationship between c-erbB-2 gene amplification and immunohistological demonstration of membrane expression of the oncoprotein (Slamon et al., 1987; Venter et al., 1987) and it has been argued that this approach is the most appropriate for routine evaluation (Barnes, 1989).”
BackgroundResultInfluentialAustin, C. D., Wen, X., Gazzard, L., Nelson, C., Scheller, R. H., & Scales, S. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509035102 · Cited by 237
Ithimakin, S., Day, K. C., Malik, F., Zen, Q., Dawsey, S. J., Bersano-Begey, T. F., Quraishi, A. A., Ignatoski, K. W., Daignault, S., Davis, A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3349 · Cited by 236
“Introduction Approximately 20% of breast cancers display amplification of the HER2 gene, a genotype associated with an aggressive course and poor outcome (1).”
BackgroundEGFR-targeted therapies in the post-genomic era
Xu, M. J., Johnson, D. E., & Grandis, J. R. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9687-8 · Cited by 236
“Similar associations exist for breast, lung, and other tumor types [4, 21, 22].”
BackgroundDynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction
Kurtz, D. M., Esfahani, M. S., Scherer, F., Soo, J., Jin, M. C., Liu, C. L., Newman, A. M., Dührsen, U., Hüttmann, A., Casasnovas, O., et al. (2019) · Cell · doi:10.1016/j.cell.2019.06.011 · Cited by 236
“Similarly, molecular dissection of differing biological features has resulted in the identification of targetable subtypes in diverse tumors, including HER2 amplifications in breast cancer and EGFR mutations in lung cancers, also leading to improved patient outcomes (Lynch et al., 2004; Paez et al., 2004; Piccart-Gebh…”
Amplification of c-erb B-2 and Aggressive Human Breast Tumors?
Ali, I. U., Campbell, G., Lidereau, R., & Callahan, R. (1988) · Science · doi:10.1126/science.3289120 · Cited by 236
Pharmacogenomics: Driving Personalized Medicine
Sadee, W., Wang, D., Hartmann, K., & Toland, A. E. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000810 · Cited by 235
Arribas, J., & Borroto, A. (2002) · Chemical Reviews · doi:10.1021/cr010202t · Cited by 235
Majewski, I. J., Nuciforo, P., Mittempergher, L., Bosma, A. J., Eidtmann, H., Holmes, E., Sotiriou, C., Fumagalli, D., Jimenez, J., Aura, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.2158 · Cited by 235
Expression of the ERBB3 gene product in breast cancer
Lemoine, N., Barnes, D., Hollywood, D., Hughes, C., Smith, P., Dublin, E., Prigent, S., Gullick, W., & Hurst, H. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.420 · Cited by 234
Moinfar, F., Okcu, M., Tsybrovskyy, O., Regitnig, P., Lax, S. F., Weybora, W., Ratschek, M., Tavassoli, F. A., & Denk, H. (2003) · Cancer · doi:10.1002/cncr.11532 · Cited by 234
“HER-2/neu, also known as c-erb-B2, is another prognostic and predictive parameter in breast carcinoma.(10) –12 It is a member of the erb-B oncogene family that is closely related to epidermal growth factor.”
BackgroundExpression of the p185 encoded by her2 oncogene in normal and transformed human tissues
Natali, P. G., Nicotra, M. R., Bigotti, A., Venturo, I., Slamon, D. J., Fendly, B. M., & Ullrich, A. (1990) · International Journal of Cancer · doi:10.1002/ijc.2910450314 · Cited by 234
Self-citationHATAKEYAMA, M., KIMURA, S., NAKA, T., KAWASAKI, T., YUMOTO, N., ICHIKAWA, M., KIM, J.-H., SAITO, K., SAEKI, M., SHIROUZU, M., et al. (2003) · Biochemical Journal · doi:10.1042/bj20021824 · Cited by 233
Prat, A., Carey, L. A., Adamo, B., Vidal, M., Tabernero, J., Cortés, J., Parker, J. S., Perou, C. M., & Baselga, J. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju152 · Cited by 233
Celecoxib: A Specific COX-2 Inhibitor with Anticancer Properties
Koki, A. T., & Masferrer, J. L. (2002) · Cancer Control · doi:10.1177/107327480200902s04 · Cited by 233
Peles, E., Ben-Levy, R., Tzahar, E., Liu, N., Wen, D., & Yarden, Y. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05737.x · Cited by 233
Leyland-Jones, B. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8481 · Cited by 233
Male breast carcinoma: An evaluation of prognostic factors contributing to a poorer outcome
Joshi, M., Lee, A. K. C., Loda, M. F., Camus, M. G., Pedersen, C. A., Heatley, G. J., & Hughes, K. S. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960201)77:3<490::aid-cncr10>3.0.co;2-# · Cited by 233
Understanding breast cancer – The long and winding road
Lukong, K. E. (2017) · BBA Clinical · doi:10.1016/j.bbacli.2017.01.001 · Cited by 232
“demonstrated the amplification of the neu oncogene in breast cancer and reported that the amplification correlatedwith poor prognoses in womenwith breast cancer [51].”
BackgroundMolecular Aspects of Mesenchymal-Epithelial Interactions
Birchmeier, C., & Birchmeier, W. (1993) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.09.110193.002455 · Cited by 232
DiGiovanna, M. P., Stern, D. F., Edgerton, S. M., Whalen, S. G., Moore, D., & Thor, A. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.055 · Cited by 232
Peña, L., Gama, A., Goldschmidt, M. H., Abadie, J., Benazzi, C., Castagnaro, M., Díez, L., Gärtner, F., Hellmén, E., Kiupel, M., et al. (2013) · Veterinary Pathology · doi:10.1177/0300985813509388 · Cited by 232
“In humans, HER2 overexpression correlates with aggressive clinicopathological features, such as the development of metastases, sensitivity to specific systemic therapies, and drug resistance.(15,95,108,132) In dogs, the significance of HER2 overexpression is unclear in mammary tumors.”
BackgroundWnt / β-Catenin Signaling Pathway as Novel Cancer Drug Targets
Luu, H., Zhang, R., Haydon, R., Rayburn, E., Kang, Q., Si, W., Park, J., Wang, H., Peng, Y., Jiang, W., et al. (2004) · Current Cancer Drug Targets · doi:10.2174/1568009043332709 · Cited by 231
“In breast cancer, HER2 positivity is correlated with decreased survival while the addition of trastuzumab to the treatment regimen has significantly improved patient survival [162-164].”
BackgroundDahabreh, I. J., Linardou, H., Siannis, F., Fountzilas, G., & Murray, S. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0001 · Cited by 231
Dowsett, M., Bartlett, J., Ellis, I., Salter, J., Hills, M., Mallon, E., Watters, A., Cooke, T., Paish, C., Wencyk, P., et al. (2003) · The Journal of Pathology · doi:10.1002/path.1313 · Cited by 231
Barok, M., Isola, J., Pályi-Krekk, Z., Nagy, P., Juhász, I., Vereb, G., Kauraniemi, P., Kapanen, A., Tanner, M., Vereb, G., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0766 · Cited by 231
Kataoka, Y., Mukohara, T., Shimada, H., Saijo, N., Hirai, M., & Minami, H. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp304 · Cited by 231
“HER2 overexpression has been repeatedly identified as a poor prognostic factor [3, 4].”
BackgroundAmplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis
Andrechek, E. R., Hardy, W. R., Siegel, P. M., Rudnicki, M. A., Cardiff, R. D., & Muller, W. J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3444 · Cited by 230
Lu, P. J., Sundquist, K., Baeckstrom, D., Poulsom, R., Hanby, A., Meier-Ewert, S., Jones, T., Mitchell, M., Pitha-Rowe, P., Freemont, P., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.22.15633 · Cited by 230
Mode of action of docetaxel – a basis for combination with novel anticancer agents
Herbst, R. S., & Khuri, F. R. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00097-5 · Cited by 230
Gallardo, A., Lerma, E., Escuin, D., Tibau, A., Muñoz, J., Ojeda, B., Barnadas, A., Adrover, E., Sánchez-Tejada, L., Giner, D., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.85 · Cited by 230
“HER2 overexpressing and/or gene amplified tumours represent approximately 25% of all BC, and they are associated with an aggressive phenotype, metastases, resistance to chemotherapy (CT), and poor prognosis (Slamon et al, 1987, 1989; Peiro et al, 2007; Nguyen et al, 2008).”
BackgroundDelay to formalin fixation effect on breast biomarkers
Khoury, T., Sait, S., Hwang, H., Chandrasekhar, R., Wilding, G., Tan, D., & Kulkarni, S. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.117 · Cited by 230
The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer
Radvanyi, L., Singh-Sandhu, D., Gallichan, S., Lovitt, C., Pedyczak, A., Mallo, G., Gish, K., Kwok, K., Hanna, W., Zubovits, J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500904102 · Cited by 230
HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis
Elkin, E. B., Weinstein, M. C., Winer, E. P., Kuntz, K. M., Schnitt, S. J., & Weeks, J. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.158 · Cited by 230
“Prevalence of HER-2-positive disease 25 15-30 [1,53]”
BackgroundBaselga, J., Lewis Phillips, G. D., Verma, S., Ro, J., Huober, J., Guardino, A. E., Samant, M. K., Olsen, S., de Haas, S. L., & Pegram, M. D. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2499 · Cited by 230
“Overexpression of HER2 occurs in approximately 15% to 20%of breast cancers and is associated with poor prognosis (1).”
HER‐2/ neu Signal Transduction in Human Breast and Ovarian Cancer
Reese, D. M., & Slamon, D. J. (1997) · STEM CELLS · doi:10.1002/stem.150001 · Cited by 229
Self-citationPredictive markers in breast cancer – the present
Payne, S. J. L., Bowen, R. L., Jones, J. L., & Wells, C. A. (2008) · Histopathology · doi:10.1111/j.1365-2559.2007.02897.x · Cited by 229
“Amplification is the predominant mechanism of gene overexpression and abnormally high levels of the 185-kDa glycoprotein are seen in approximately 18–20% of breast cancers.(23) HER-2 positivity is associated with highgrade tumours, lymph node involvement,(24) a higher rate of disease recurrence and mortality, and thus…”
BackgroundInhibition of MUC4 Expression Suppresses Pancreatic Tumor Cell Growth and Metastasis
Singh, A. P., Moniaux, N., Chauhan, S. C., Meza, J. L., & Batra, S. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2636 · Cited by 229
“HER2 has been implicated in cell proliferation via initiating signals for growth regulatory pathways (24, 34).”
BackgroundThe Use of Lentinan for Treating Gastric Cancer
Ina, K., Kataoka, T., & Ando, T. (2013) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520611313050002 · Cited by 229
Enabling individualized therapy through nanotechnology
Sakamoto, J. H., van de Ven, A. L., Godin, B., Blanco, E., Serda, R. E., Grattoni, A., Ziemys, A., Bouamrani, A., Hu, T., Ranganathan, S. I., et al. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2009.12.011 · Cited by 229
Ignatiadis, M., Kallergi, G., Ntoulia, M., Perraki, M., Apostolaki, S., Kafousi, M., Chlouverakis, G., Stathopoulos, E., Lianidou, E., Georgoulias, V., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4758 · Cited by 229
PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials
Dey, N., De, P., & Leyland-Jones, B. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.037 · Cited by 229
“HER2 is amplified/overexpressed in about 20–25% of BC and is associated with tumor aggressiveness, resulting in recurrent disease progression or shorter overall survival (Slamon et al., 1987).”
BackgroundBosher, J. M., Williams, T., & Hurst, H. C. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.3.744 · Cited by 229
Somatic Mutations of ERBB2 Kinase Domain in Gastric, Colorectal, and Breast Carcinomas
Lee, J. W., Soung, Y. H., Seo, S. H., Kim, S. Y., Park, C. H., Wang, Y. P., Park, K., Nam, S. W., Park, W. S., Kim, S. H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0976 · Cited by 228
“The humanized antibody trastuzumab (Herceptin) against the overexpressed ERBB2 is proven to be effective in treating breast cancers with ERBB2 amplification (9, 10).”
BackgroundHuman Tumor Antigens and Cancer Immunotherapy
Vigneron, N. (2015) · BioMed Research International · doi:10.1155/2015/948501 · Cited by 228
“Three major types of catalytic activities are associated with proteasome function: the PGPH (peptidyl-glutamyl peptide bond hydrolysing) or caspase-like activity, the trypsin-like activity, and the chymotrypsin-like activity, which cleave after acidic, basic, and hydrophobic residues, respectively.”
BackgroundRégnier, C. H., Tomasetto, C., Moog-Lutz, C., Chenard, M.-P., Wendling, C., Basset, P., & Rio, M.-C. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.43.25715 · Cited by 228
“CART1 has been mapped on the q11-q12 region of the long arm of chromosome 17 (Tomasetto et al., 1995), a locus that includes the oncogene c-erbB2 whose overexpression is correlated with a shorter overall and disease-free survival for breast cancer patients (Slamon et al., 1987; Muss et al., 1994).”
BackgroundMammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity.
Muthuswamy, S. K., Siegel, P. M., Dankort, D. L., Webster, M. A., & Muller, W. J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.1.735 · Cited by 228
Ma, F., Li, Q., Chen, S., Zhu, W., Fan, Y., Wang, J., Luo, Y., Xing, P., Lan, B., Li, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.6179 · Cited by 228
Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer
Schneider, P. M. (1990) · Lung Cancer · doi:10.1016/0169-5002(90)90280-y · Cited by 228
“We conclude that in contrast to studies in human breast cancer (12-14, 30), amplification of the c-erbB-2 gene is rare in human NSCLC.”
BackgroundResultInvolvement of Notch1 in the development of mouse mammary tumors
Diévart, A., Beaulieu, N., & Jolicoeur, P. (1999) · Oncogene · doi:10.1038/sj.onc.1202991 · Cited by 227
“The overexpression of the c-neu/erbB2 protein represents one of the most frequent genetic alterations of human breast cancer (for review, see Salomon et al., 1995) and correlate with a more aggressive breast cancer phenotype (Slamon et al., 1987).”
BackgroundHasanzadeh, M., Shadjou, N., & de la Guardia, M. (2015) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2015.03.016 · Cited by 227
Feldkamp, M. M., Feldkamp, M. M., Lala, P., Lau, N., Roncari, L., Guha, A., Guha, A., & Guha, A. (1999) · Neurosurgery · doi:10.1097/00006123-199912000-00034 · Cited by 227
Ishikawa, T., Seto, M., Banno, H., Kawakita, Y., Oorui, M., Taniguchi, T., Ohta, Y., Tamura, T., Nakayama, A., Miki, H., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2008634 · Cited by 227
Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer
Chandarlapaty, S., Sakr, R. A., Giri, D., Patil, S., Heguy, A., Morrow, M., Modi, S., Norton, L., Rosen, N., Hudis, C., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1785 · Cited by 227
HER-2/neu expression: A major prognostic factor in endometrial cancer
Hetzel, D. J., Wilson, T. O., Keeney, G. L., Roche, P. C., Cha, S. S., & Podratz, K. C. (1992) · Gynecologic Oncology · doi:10.1016/0090-8258(92)90103-p · Cited by 227
Hyperactivation of MAPK Induces Loss of ERα Expression in Breast Cancer Cells
Oh, A. S., Lorant, L. A., Holloway, J. N., Miller, D. L., Kern, F. G., & El-Ashry, D. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.8.0678 · Cited by 226
Shi, L., Dong, B., Li, Z., Lu, Y., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., Lin, B., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2254 · Cited by 226
MYC-Driven Pathways in Breast Cancer Subtypes
Fallah, Y., Brundage, J., Allegakoen, P., & Shajahan-Haq, A. N. (2017) · Biomolecules · doi:10.3390/biom7030053 · Cited by 226
“HER2 breast cancer is associated with increased proliferative indices, metastasis and recurrence [29].”
BackgroundZou, Y., Zheng, S., Xie, X., Ye, F., Hu, X., Tian, Z., Yan, S.-M., Yang, L., Kong, Y., Tang, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30217-7 · Cited by 226
Outgrowth of single oncogene-expressing cells from suppressive epithelial environments
Leung, C. T., & Brugge, J. S. (2012) · Nature · doi:10.1038/nature10826 · Cited by 226
Lobbezoo, D. J. A., van Kampen, R. J. W., Voogd, A. C., Dercksen, M. W., van den Berkmortel, F., Smilde, T. J., van de Wouw, A. J., Peters, F. P. J., van Riel, J. M. G. H., Peters, N. A. J. B., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.127 · Cited by 226
“Even though in the pretrastuzumab era, the amplification of HER2 in breast cancer was demonstrated to be a strong unfavourable prognostic factor (Slamon et al, 1987).”
BackgroundLaé, M., Couturier, J., Oudard, S., Radvanyi, F., Beuzeboc, P., & Vieillefond, A. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp488 · Cited by 226
“In breast cancer, HER2 overexpression is the result of an amplification of the HER2 gene, leading to an increase in HER2 messenger RNA levels and a concomitant overexpression of the HER2 receptor on the tumor cell surface [6].”
BackgroundBarok, M., Tanner, M., Köninki, K., & Isola, J. (2011) · Breast Cancer Research · doi:10.1186/bcr2868 · Cited by 226
“Its overexpression occurs in 15 to 20% of primary human breast cancers and is associated with aggressive growth and poor clinical outcomes [1,2].”
BackgroundDeficiency of connexin43 gap junctions is an independent marker for breast tumors.
Laird, D. W., Fistouris, P., Batist, G., Alpert, L., Huynh, H., Carystinos, G. D., & Alaoui-Jamali, M. (1999) · PubMed · Cited by 226
Rao, A. V., Ray, M. R., & Rao, L. G. (2006) · Advances in Food and Nutrition Research · doi:10.1016/s1043-4526(06)51002-2 · Cited by 225
King, C. R., Borrello, I., Bellot, F., Comoglio, P., & Schlessinger, J. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb02991.x · Cited by 225
Primary Central Nervous System Posttransplant Lymphoproliferative Disorders
Castellano-Sanchez, A. A., Li, S., Qian, J., Lagoo, A. S., Weir, E., & Brat, D. J. (2004) · American Journal of Clinical Pathology · doi:10.1309/n82ctq1j0xevefqb · Cited by 225
Heitz, F., Harter, P., Lueck, H.-J., Fissler-Eckhoff, A., Lorenz-Salehi, F., Scheil-Bertram, S., Traut, A., & Bois, A. D. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.06.027 · Cited by 224
“As mentioned above, HER2-overexpression is associated with a more aggressive course of disease.(13) According to ER status, HER2-overexpressing BC can be classified into two subgroups: the HER2 subtype (ER-negative) and the Luminal B subtype (ER-positive).”
BackgroundYoon, S., Lee, M.-Y., Park, S. W., Moon, J.-S., Koh, Y.-K., Ahn, Y.-H., Park, B.-W., & Kim, K.-S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702854200 · Cited by 224
Angiopoietins in tumours: the angiogenic switch
Tait, C. R., & Jones, P. F. (2004) · The Journal of Pathology · doi:10.1002/path.1618 · Cited by 223
“HER-2 (neu, c-erb-2) is a tyrosine kinase growth factor receptor whose overexpression is a marker of an aggressive breast cancer and an indicator of poor prognosis [87].”
BackgroundKulukian, A., Lee, P., Taylor, J., Rosler, R., de Vries, P., Watson, D., Forero-Torres, A., & Peterson, S. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0873 · Cited by 222
Pegram, M. D., Konecny, G., & Slamon, D. J. (2000) · Cancer Treatment and Research · doi:10.1007/978-1-4757-3147-7_4 · Cited by 222
Self-citationAdjuvant Trastuzumab: A Milestone in the Treatment of HER-2-Positive Early Breast Cancer
Baselga, J., Perez, E. A., Pienkowski, T., & Bell, R. (2006) · The Oncologist · doi:10.1634/theoncologist.11-90001-4 · Cited by 222
EGF-stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions.
Stern, D. F., & Kamps, M. P. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb02906.x · Cited by 222
Cruz, E., & Kayser, V. (2019) · Biologics: Targets and Therapy · doi:10.2147/btt.s166310 · Cited by 221
“HER2 overexpression is detected in 15–20% of breast cancers, and this subset is associated with poor prognosis and higher rates of recurrence.(30,31)”
BackgroundYu, X., Sharma, K. D., Takahashi, T., Iwamoto, R., & Mekada, E. (2002) · Molecular Biology of the Cell · doi:10.1091/mbc.01-08-0411 · Cited by 221
“EGFR has several ligands with similar structures, including EGF, transforming growth factor , heparin-binding EGF-like growth factor (HB-EGF), amphiregulin, betacellulin, and epiregulin (Marquart et al., 1984; Shoyab et al., 1989; Higashiyama et al., 1991; Shing et al., 1993; Toyoda et al., 1995).”
BackgroundLal, P., Tan, L. K., & Chen, B. (2005) · American Journal of Clinical Pathology · doi:10.1309/ymj3-a83t-b39m-rut9 · Cited by 221
Barnes, D. M., Dublin, E. A., Fisher, C. J., Levison, D. A., & Millis, R. R. (1993) · Human Pathology · doi:10.1016/0046-8177(93)90158-d · Cited by 221
Ferraro, E., Drago, J. Z., & Modi, S. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01459-y · Cited by 220
“Historically, HER2-positive breast cancer (BC) has been recognized to have a poor prognosis, with a median overall survival of 15 months with traditional chemotherapy treatments in the metastatic setting [1].”
BackgroundHouston, S. J., Plunkett, T. A., Barnes, D. M., Smith, P., Rubens, R. D., & Miles, D. W. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690196 · Cited by 220
“…of c-erbB2 has been reported in 10Ð40% of primary breast cancers, and has been associated with a worse prognosis in patients with node-positive (Slamon et al, 1987, 1989; Gullick et al, 1991) and node-negative disease (Gullick et al, 1991; Press et al, 1993, 1997; OÕMalley et al, 1996;…”
BackgroundMethodAmplification of oncogenes in human cancer cells
Schwab, M. (1998) · BioEssays · doi:10.1002/(sici)1521-1878(199806)20:6<473::aid-bies5>3.0.co;2-n · Cited by 220
Adaptive Regulation at the Cell Surface by N ‐Glycosylation
Dennis, J. W., Lau, K. S., Demetriou, M., & Nabi, I. R. (2009) · Traffic · doi:10.1111/j.1600-0854.2009.00981.x · Cited by 219
“Surface levels of EGFR family members are commonly increased in breast cancer, and correlate with reduced survival time (69).”
BackgroundCombinatorial biomarker expression in breast cancer
Rakha, E. A., Reis-Filho, J. S., & Ellis, I. O. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0746-x · Cited by 219
“In HR? tumours, the mortality rate is appears constant overtime from diagnosis, whilst the rate for HR- tumours is high during the first 3–5 years and then declines showing a plateau curve of survival.”
BackgroundInfluentialMechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c4
Albanell, J., Codony, J., Rovira, A., Mellado, B., & Gascón, P. (2003) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4615-0081-0_21 · Cited by 219
Her-2/neu Overexpression and Amplification in Uterine Papillary Serous Carcinoma
Slomovitz, B. M., Broaddus, R. R., Burke, T. W., Sneige, N., Soliman, P. T., Wu, W., Sun, C. C., Munsell, M. F., Gershenson, D. M., & Lu, K. H. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.154 · Cited by 219
B7-H4 Is Highly Expressed in Ductal and Lobular Breast Cancer
Tringler, B., Zhuo, S., Pilkington, G., Torkko, K. C., Singh, M., Lucia, M. S., Heinz, D. E., Papkoff, J., & Shroyer, K. R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1658 · Cited by 219
“194z IIa 35 6 (17) 2 (6) 3 (9) 24 (69) 18.”
BackgroundInfluentialTrastuzumab-containing regimens for metastatic breast cancer
Balduzzi, S., Mantarro, S., Guarneri, V., Tagliabue, L., Pistotti, V., Moja, L., & D'Amico, R. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006242.pub2 · Cited by 218
HER-2 amplification is highly homogenous in gastric cancer
Marx, A. H., Tharun, L., Muth, J., Dancau, A., Simon, R., Yekebas, E. F., Kaifi, J. T., Mirlacher, M., Brümmendorf, T. H., Bokemeyer, C., et al. (2009) · Human Pathology · doi:10.1016/j.humpath.2008.11.014 · Cited by 218
“Her-2 alterations play a role in the development and progression of many human cancers and have been linked to poor prognosis [1-6].”
BackgroundHoang, M. P., Şahin, A. A., Ordóǹez, N. G., & Sneige, N. (2000) · American Journal of Clinical Pathology · doi:10.1309/vacp-vlqa-g9dx-vudf · Cited by 218
Lara‐Medina, F., Pérez‐Sánchez, V., Saavedra‐Pérez, D., Blake‐Cerda, M., Arce, C., Motola‐Kuba, D., Villarreal‐Garza, C., González‐Angulo, A. M., Bargalló, E., Aguilar, J. L., et al. (2011) · Cancer · doi:10.1002/cncr.25961 · Cited by 217
Curigliano, G., Mueller, V., Borges, V., Hamilton, E., Hurvitz, S., Loi, S., Murthy, R., Okines, A., Paplomata, E., Cameron, D., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2021.12.005 · Cited by 217
Self-citationSingh, J. K., Farnie, G., Bundred, N. J., Simões, B. M., Shergill, A., Landberg, G., Howell, S. J., & Clarke, R. B. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1063 · Cited by 217
“Up to 25% of breast cancers overexpress human EGF receptor 2 (HER2), which confers a higher rate of recurrence and mortality (10).”
BackgroundWolf, C., Rouyer, N., Lutz, Y., Adida, C., Loriot, M., Bellocq, J., Chambon, P., & Basset, P. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1843 · Cited by 217
Ligand-induced ErbB receptor dimerization
Lemmon, M. A. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.10.024 · Cited by 216
“ErbB2 overexpression is also strongly associated with breast cancer [35] –and it is the target of the Herceptin antibody [15, 36].”
Background
Metadata
- Authors
- Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L.
- Affiliations
- University of California, Los Angeles (US)
- The University of Texas at San Antonio Health Science Center (US)
- Genentech (US)
- Venue
- Science
- Published
- 1987-01-09
- Volume
- 235
- Issue
- 4785
- Pages
- 177-182
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2141393790
- Cited by
- 11,760
- References
- 44
- Citations by year
- 2026: 209 · 2025: 230 · 2024: 301 · 2023: 309 · 2022: 302 · 2021: 346 · 2020: 336 · 2019: 325 · 2018: 344 · 2017: 395 · 2016: 416 · 2015: 433 · 2014: 486 · 2013: 549 · 2012: 459
- FWCI
- 103.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA36827, CA-30195)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- gene amplification, breast cancer, prognostic factors, relapse, overall survival, lymph node-positive disease, hormone receptor status, ErbB family, epidermal growth factor receptor
- MeSH terms
- Axilla, Breast Neoplasms, DNA, Female, Gene Amplification, Humans, Lymph Nodes, Neoplasm Recurrence, Local, Nucleic Acid Hybridization, Oncogenes, Prognosis, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.